Drugs / zocaglusagene nuzaparvovec
zocaglusagene nuzaparvovec
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04174105 | Oct 2020 → Feb 2035 expected | glycogen storage disease due to acid maltase deficiency, late-onset | Astellas Gene Therapies | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zocaglusagene nuzaparvovec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04174105 ↗ |
| Known as | AT-845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314721 ↗ |
| Known as | Zocaglusagen nuzaparvovec | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314721 ↗ |